Dr. Courtney DiNardo Sheds Light on FDA Fast Track Designation and Its Impact on Drug Development

Courtney DiNardo, MD, MSCE, a clinical researcher in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center and lead author on a study presented at EHA 2023, evaluating a new therapy, IO-202 (Immune-Onc Therapeutics) for chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML), detailed how FDA fast track designations impact drug development and how recuitment and diverse representation in...